| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Email: |
eric_feng1954@126.com |
| Products Intro: |
Product Name:LUMIRACOXIB
Purity:99%+ Package:1Kg,10kg,100kg,1000KG
|
| Company Name: |
Wuhan Yanzhe Technology Co., Ltd
|
| Tel: |
15527250409 |
| Email: |
wenhaotian12@163.com |
| Products Intro: |
Product Name:Lumiracoxib
Purity:98% HPLC Package:1Mg ; 5Mg;10Mg ;100Mg;250Mg ;500Mg ;1g;2.5g ;5g ;76g;
|
| Company Name: |
Triveni chemicals
|
| Tel: |
08048762458 |
| Email: |
sales@trivenichemical.com |
| Products Intro: |
Product Name:Lumiracoxib
|
| Company Name: |
United States Biological
|
| Tel: |
800.520.3011 or 781.639.5092 |
| Email: |
chemicals@usbio.net |
| Products Intro: |
Product Name:Lumiracoxib
|
|
| | LUMIRACOXIB Basic information |
| Product Name: | LUMIRACOXIB | | Synonyms: | LUMIRACOXIB | | CAS: | | | MF: | C15H13ClFNO2 | | MW: | 293.72 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File |  |
| | LUMIRACOXIB Chemical Properties |
| Melting point | 136-150?C | | storage temp. | -20°C Freezer | | solubility | DMSO (Slightly), Methanol (Slightly) | | form | Solid | | color | Pale Yellow |
| | LUMIRACOXIB Usage And Synthesis |
| Description | Lumiracoxib, a selective COX-2 inhibitor discovered and
developed by Novartis, was approved in September, 2003 in
the UK for the symptomatic relief of osteoarthritis and short term relief of moderate to severe acute pain associated with
primary dysmenorrhea, dental surgery and orthopedic surgery. After an initial not approvable letter issued by FDA in
September 2003, Novartis expects to re-submit a NDA by
early 2006 following the completion of several studies
requested by FDA. | | Uses | Treatment of rheumatoid arthritis, osteoarthritis, and pain prevention. | | Uses | Lumiracoxib is a selective cyclooxygenase-2-(COX-2) inhibitor and an anti-inflammatory agent (1,2,3,4). | | Pharmacokinetics | Lumiracoxib is rapidly absorbed, with an oral bioavailability of 74%, and
reaches a maximum plasma concentration 2 hour after dosing. It is highly plasma protein bound and has a short
elimination half-life of approximately 4 hours, demonstrating linear plasma pharmacokinetics with no accumulation
during multiple dosing. | | Clinical Use | Lumiracoxib is a selective COX-2 inhibitor developed for the treatment of osteoarthritis, rheumatoid
arthritis, and acute pain. It structurally differs from the other selective COX-2 inhibitors in being a phenylacetic acid
with a carboxylic acid group (pKa = 4.7). | | Synthesis | Since the original patent on the
discovery of lumiracoxib (XIV) disclosed the first synthesis
of this compound, several approaches to the synthesis
of lumiracoxib (XIV) have been detailed in the subsequent
process patent. In all the routes, the key to the synthesis
was the ring opening of lactam 121. Coupling of pbromotoluene
(116) with 2-chloro-6-fluoroaniline (117) in
the presence of palladium catalyst Pd(dba)3, tributyl
phosphine and sodium t-butoxide in toluene provided
aniline intermediate 118 . Acylation with
chloroacetylchloride (119) at 90°C neat gave chloride
intermediate 120. Cyclization in the presence of aluminum
chloride at 160 to 170°C gave the key lactam 121, which
was subsequently opened with sodium hydroxide in boiling
ethanol water mixture to provide lumiracoxib (XIV). 
| | Metabolism | Lumiracoxib is extensively metabolized involving oxidation of its 5-Me group and
4′-hydroxylation of the dihalogenated aromatic ring. The major in vitro oxidative pathways is catalyzed primarily by
CYP2C9. Lumiracoxib and its metabolites are excreted via renal and fecal routes in approximately equal amounts.
The COX-2 selectivity was confirmed by a lack of inhibition of arachidonic acid and collagen-induced platelet
aggregation. As with other selective coxibs, lumiracoxib exhibits a reduced incidence of gastroduodenal erosions
compared with that of naproxen. It was approved for use in the United Kingdom and the United States in 2007. |
| | LUMIRACOXIB Preparation Products And Raw materials |
|